Form 4: Amneal Pharmaceuticals Director Alva Emily Peterson Acquires 40,258 Restricted Stock Units

Director Alva Emily Peterson of Amneal Pharmaceuticals acquired 40,258 restricted stock units on May 2, 2024, according to a recent SEC filing.

Summary

• On May 2, 2024, Alva Emily Peterson, a director of Amneal Pharmaceuticals, acquired 40,258 restricted stock units (RSUs).
• Each RSU represents a contingent right to receive one share of Amneal Pharmaceuticals' Class A Common Stock.
• The RSUs vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant.
• Following the transaction, Peterson directly owns 40,258 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to stock unit grants, which is neither overtly positive nor negative.

Positives

• The acquisition of restricted stock units by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to the market.

Stakeholder Impact

• The acquisition of restricted stock units by a director may have a slightly positive impact on shareholder sentiment.

Key Dates